OTLC Oncotelic Therapeutics

Filed: 2 Mar 21, 7:00am






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)

March 1, 2021



(Exact name of registrant as specified in its charter)


Delaware 000-21990 13-3679168

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


29397 Agoura Road Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)


Registrant’s telephone number, including area code

(650) 635-7000



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of class Trading Symbols Name of each exchange on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]






Item 8.01Other Events


On March 1, 2021 Mateon Therapeutics, Inc. issued press release announcing:


We have shown that the active component of PulmoHealTM is active against influenza virus consistent with the broad-spectrum activity for PulmoHealTM which is confirmed by its reported activity against variants, B1.1.7 and B1.351 of SARS-CoV-2. These escape variants have been reported to be more contagious and potentially resistant to vaccines.


Additionally, Mateon has further its relationship with IBM by signing a joint development agreement with IBM Watson Health Research division to collectively work on AI models for respiratory assessments.


The press release is attached to this Current Report on Form 8-K as Exhibit 99.1.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No. Description Incorporation by reference
99.1 Publications of PulmoHeal Filed herewith.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 Mateon Therapeutics, Inc.
Date: March 2, 2021/s/ Vuong Trieu
 By:Vuong Trieu
  Chief Executive Officer